69 results about "Stem-cell therapy" patented technology

A composition comprising an expanded population of cells can be used in therapy, wherein the cells have been expanded by a method comprising: i) obtaining an isolated population of HSPCs; ii) culturing the isolated population of HSPCs in the presence of a histone deacetylase inhibitor (HDAC inhibitor) to form a cultured population; iii) adding to the cultured HSPC population an aminothiol compound having the formula RNH (CnH2n) NH (CnH2n) SX wherein R is hydrogen, an aryl group, an acyl group or an alkyl group containing from 1 to 7 carbon atoms, each n having a value of from 2 to 6, and X is H or PO3H2 to form expanded cells; or a pharmaceutically acceptable salt thereof.

The invention relates to the field of medical information analysis and artificial intelligence, and discloses a human body case multifunctional stem cell treatment analysis system based on an AI algorithm, and the system comprises a data collection and integration module which is used for collecting, cleaning, standardizing and storing data information related to human body multifunctional stem cell treatment from multi-source heterogeneous data; the AI model construction and optimization module is used for performing feature extraction, model training, optimization and evaluation on the data to generate a prediction model; and the treatment effect prediction and decision-making auxiliary module is used for analyzing the treatment effect of the patient based on the prediction model. Through multi-source data integration, deep learning modeling and personalized treatment scheme recommendation technologies, the problems that in the prior art, data processing is dispersed, the variable relation is complex, modeling is difficult, personalized treatment lacks basis, and data transmission efficiency and safety are insufficient are solved, and accurate analysis and safety management of stem cell treatment are achieved.

The invention provides an immune regulation type stem cell as well as a preparation method and application thereof in preparation of a medicine for treating lupus erythematosus, and belongs to the technical field of stem cell treatment. According to the preparation method of the immunomodulatory stem cells, the mesenchymal stem cells capable of remarkably improving the secretion capacity of IL-10 are screened by adopting CD106 + / CD274 + double-labeled magnetic beads for sorting, and the immunomodulatory stem cells which are definite in curative effect, small in side effect and high in immunomodulatory efficiency are prepared by performing hypoxia pretreatment, improving the homing capacity of the stem cells and performing induction by using immunomodulatory factors in three stages. The immunoregulation stem cell has a remarkable curative effect on systemic lupus erythematosus.

The invention relates to the technical field of curative effect prediction, in particular to a curative effect prediction method and system for treating spinal cord injury by stem cells, and the method comprises the following steps: obtaining a multi-parameter metabolism sequence and constructing an activation rhythm map, recognizing a neural restoration synchronization section, extracting a metabolism dominant path and evaluating electrical signal response, generating a para-position map layer and predicting a curative effect trend. According to the method, through introduction of cross-time-sequence metabolism and trend synchronous identification of electrophysiological indexes, dynamic mapping of stem cell activation rhythms is realized, neural axon morphological changes and cerebrospinal fluid metabolism parameters are linked, and distribution positions of key response points in a treatment cycle are determined; the method comprises the following steps: establishing a causal path based on a sequence of metabolic mutation and neural restoration events, extracting an evolution stage dominated by a metabolic driving effect, marking a matching trend of a curative effect response and an intervention path on a time axis, identifying the number and positions of trend convergence, withdrawal and interruption areas, and realizing collaborative prediction of a restoration progress and a curative effect trend.

Exemplary light control devices and methods provide a regional variation of visual information and sampling (“V-VIS”) of an ocular field of view that improves or stabilizes vision, ameliorates a visual symptom, reduces the rate of vision loss, or reduces the progression of an ophthalmic or neurologic condition, disease, injury or disorder. The V-VIS devices and methods generate a moving aperture effect anterior to a retina that samples and delivers to the retina environmental light from an ocular field of view at a sampling rate between 50 hertz and 50 kilohertz. Certain of these V-VIS devices and methods may be combined with augmented or virtual reality, vision measurement, vision monitoring, or other therapies including, but not limited to, pharmacological, gene, retinal replacement and stem cell therapies.

The invention discloses a surface-enhanced Raman probe as well as a preparation method and application thereof, and belongs to the technical field of biomedical imaging and stem cell therapy. The preparation method comprises the following steps: coating an ultrathin silver shell layer on the surface of gold nanoparticles to obtain Au-coated Ag particles; 4-sulfydryl phenylboronic acid pinacol ester molecules are modified on the surface of Au (at) Ag to form a Raman report layer, then sulfydryl-polyethylene glycol is introduced to realize biological orthogonal coupling, and the modified SERS probe is obtained through bovine serum albumin modification; jointly incubating the modified SERS probe and the azidation-labeled mouse bone marrow mesenchymal stem cells, so as to form an mmol / LSC-SERS composite probe; the obtained probe has good biocompatibility, stability and anti-interference capability and is suitable for a complex physiological environment, and the preparation method is simple and good in repeatability, is completely carried out in a water phase and does not need an organic solvent.

The present invention relates to a method for producing tonsil-derived mesenchymal stem cells. According to the production method of the present invention, a large amount of tonsil-derived mesenchymal stem cells can be produced by isolating mononuclear cells from tonsil tissues and subculturing the mononuclear cells by an optimized normalization method, and the method can be advantageously used for developing a stem cell therapeutic agent.

The invention provides a method for producing functional spinal cord GABAergic neural precursor cells from human pluripotent stem cells, which successfully realizes directional differentiation of the human pluripotent stem cells by adopting a feeder-layer-free culture method based on a three-stage in-vitro induced differentiation strategy. The invention further provides application of the cells obtained through the method in treatment of spinal cord injury, a novel strategy based on the functional spinal cord GABAergic neural precursor cells is provided, a new thought and means are provided for treatment of spinal cord injury, and stem cell treatment is expected to proceed towards clinical precision and industrial application.

This application belongs to the technical field of stem cell therapy, and discloses a composition for treating degenerative arthritis and its application. The composition contains adipose stem cells in a mass fraction of 20-60%, bone marrow mesenchymal stem cells in a mass fraction of 10-30%, and traditional Chinese medicine in a mass fraction of 10-50%. By improving the culture medium of adipose stem cells, this application obtains adipose stem cells with stronger proliferation ability, and its miRNA-140 is highly expressed. After being compounded with bone marrow mesenchymal stem cells and turmeric powder in proportion, it can effectively inhibit inflammatory factors and accelerate the recovery of cartilage tissue.

The present invention relates to the field of stem cell technology and specifically discloses an application of mesenchymal stem cells (MSCs) for the treatment of lower extremity venous ischemia. This application involves pre-treating human mesenchymal stem cells (hMSCs) with the SDF1-FGF2 fusion protein. This pre-treatment significantly enhances the cell viability, blood flow recovery, and anti-inflammatory effects of hMSCs in a lower extremity venous ischemia model. When hMSCs pre-treated with SDF1-FGF2 were injected into mice modeling venous ischemia, they demonstrated superior effects compared to untreated cells in improving blood perfusion, reducing inflammatory responses, and restoring motor function. This method provides a highly effective stem cell therapy strategy for vascular diseases such as lower extremity venous ischemia.

The invention relates to a method for differentiating mesenchymal stem cells into adipose cells, which comprises the following steps: (1) culturing early passage mesenchymal stem cells to a confluence degree close to 100%, and ensuring enough basic cell quantity; (2) replacing the basic culture medium with a fat induction culture medium, and performing induced differentiation for 14-21 days; (3) observing a saturated oil red O dyeing result; and (4) the method can be applied to differentiation of mesenchymal stem cells in animal cell culture meat into adipocytes to form lipids, and is suitable for differentiation of mesenchymal stem cells into adipocytes in stem cell treatment and health care.

The present disclosure relates to cannabinoid compositions used in combination with stem cell therapies. These compositions can be encapsulated (e.g., microencapsulated). In particular, these compositions can be administered to a subject, such as through oral consumption or topical treatment.

The present invention relates to the use of corneal cell-derived mitochondria for the prevention or treatment of corneal damage or corneal endothelial cell diseases. It has been confirmed that mitochondria isolated from corneal endothelial cells differentiated from induced pluripotent stem cells (iPSCs) of the present invention alleviate the inflammatory response of corneal endothelial cells in an inflammatory environment, restore the integrity and function of corneal endothelial cells, and, when delivered into heterologous primary corneal endothelial cells, suppress inflammatory responses, particularly inflammation caused by physical damage, and promote the regeneration of corneal endothelial cells. Therefore, mitochondria possessing such effects can overcome the tumorigenic limitations of conventional stem cell therapies, and due to their ease of production and minimal regulatory requirements, they offer excellent cost-effectiveness and broad applicability.

A silicon-anchored hardware enforcement system enables low-latency, cryptographically gated execution of artificial intelligence for stem cell therapy and regenerative medicine. A Sovereign Identity Token derived from a Physical Unclonable Function (PUF) permanently binds model decryption to a specific hardware instance and restricts execution to a Trusted Execution Environment synchronized to a hardware-protected Safety Epoch. Encrypted AI model weights are decryptable only upon successful hardware validation. Multimodal clinical inputs, including genetic, imaging, and structured patient data, are integrated through a hardware-constrained fusion architecture that operates under enforced biological safety parameters. FPGA-implemented predicate logic evaluates defined biological safety conditions at sub-millisecond latency, and an ASIC-based nullification circuit irreversibly suppresses outputs that violate hardware-defined thresholds within a bounded millisecond response time. A distributed revocation protocol propagates credential invalidation across networked nodes within sub-second latency while preserving reduced-capacity safe mode operation. A permissioned provenance ledger records hardware-attested execution events and supports automated regulatory documentation. The system provides secure clinical deployment, federated research enablement, and verifiable auditability for high-risk therapeutic environments.

The invention relates to a degradable cell micro-nano patch and application thereof in stem cell treatment and tissue repair, the micro-nano patch is composed of a drug carrying layer and a cell adhesion layer, the size is between 100 nanometers and 100 micrometers, and the thickness is between 10 nanometers and 10 micrometers. The degradable cell micro-nano patch can load and slowly release various biochemical factors, can be adsorbed on the surface of stem cells to be injected and migrated along with the cells, releases the factors around implanted cells, accurately regulates and controls the extracellular microenvironment, enhances the activity of the implanted cells and the capability of directionally differentiating the implanted cells into target cells, and has a good application prospect. The treatment effect of the stem cells is greatly improved, the stem cells are not prone to inactivation in the body, the stem cells are tightly attached to the cells when transplanted into the body together with the cells, and accurate and efficient regulation and control of the cells are achieved.

The utility model discloses a cell culture detection box for stem cell treatment, and relates to the technical field of cell culture. The detection device comprises a detection box body, a mounting plate is arranged in the detection box body, a plurality of fixing grooves are formed in the mounting plate, a two-way screw rod is rotationally matched in the fixing grooves, a connecting rod is arranged at one end of the two-way screw rod, a handle is arranged at one end of the connecting rod, two moving blocks are in threaded fit with the two-way screw rod, and connecting plates are arranged on the moving blocks. And an elastic piece is arranged on one side of the connecting plate. According to the culture dish fixing device, the arc-shaped fixing plates located on the two moving blocks can be driven to move oppositely under the rotation of the two-way lead screw, so that the culture dishes can be fixed, and when the culture dishes with different sizes are fixed under the arrangement of the elastic pieces, the culture dishes can be fixed more conveniently. The culture dish is further fixed through the pressure of the elastic piece, so that the culture dish can be fixed more stably.

The present disclosure relates to cannabinoid compositions used in combination with stem cell therapies. These compositions can be encapsulated (e.g., microencapsulated). In particular, these compositions can be administered to a subject, such as through oral consumption or topical treatment.

The present disclosure provides for a method of characterizing a nucleic acid network comprising: providing a biological sample on a substrate, wherein the biological sample comprises the nucleic acid network; applying spatially-aware graph neural networks (spaGNN) to the biological sample to obtain characterization data; and analyzing the characterization data. Also provided herein is a method of providing stem cell therapy to a subject in need thereof comprising: performing the method disclosed herein to a stem cell; and administering the stem cell to the subject. Further disclosed herein is a kit comprising a stem cell targeting reagent and an organelle map, wherein the organelle map comprises data indicating identification and proximity of RNA inside of an organelle and outside of an organelle.

Disclosed herein are cytokine constructs that include a delivery vehicle, and at least one cytokine or one decoy receptor. By adjusting the types and density of cytokines on the constructs, they can be tailored for both local and systemic treatment of patients with cancers and other immune-related diseases, such as autoimmune diseases. Additionally, the cytokine constructs can be used ex vivo to expand and activate cells from patients or healthy subjects before re-infusing the activated cells back into patients, which benefits adoptive and stem cell therapies. These constructs display improved half-life and stability of cytokines, enabling reducing doses, and minimizing toxicity from unintended effects of free cytokines. Furthermore, the constructs allow for co-delivery of other therapeutics, such as antibodies, small molecule inhibitors, chemotherapeutics, oligonucleotides, adjuvants, and antigens.

The present invention relates to adipose-derived stem cells (ASCs) and compositions, as well as methods for preparing and using such ASCs and compositions for therapy.

The invention discloses a smooth muscle stem cell treatment optimization method and system for female pelvic floor dysfunction. First pelvic floor image data collected from pelvic floor muscle parts, first pelvic floor function parameters for evaluating pelvic floor functions and first tissue state parameters of smooth muscle cells for stem cell culture are processed to obtain first culture factor characteristics; constructing a pelvic floor dysfunction assessment optimization model by utilizing the first culture factor characteristics and a first smooth muscle stem cell culture method, inputting the second culture factor characteristics of an optimization target to be assessed into the model to obtain a second culture method, and helping to perform specific culture of smooth muscle stem cells. Therefore, doctors are assisted in personalized pelvic floor dysfunction repair for different patients, the treatment effect is improved, and damage to surrounding tissues of the patients is reduced. By building the improved deep learning model, the culture time of the smooth muscle stem cells is shortened, accurate and low-damage pelvic floor treatment is promoted, and the pertinence of culture of the smooth muscle stem cells is improved.

Methods of using pulsed focused ultrasound (pFUS) therapy to treat pancreatic disorders such as type 1 diabetes, pancreatitis, and pancreatic cancer are provided. The methods utilize pulsed focused ultrasound (pFUS) therapy either by itself or in combination with islet transplantation and / or stem cell therapy to promote regeneration of damaged pancreatic tissue, increase insulin secretion in response to glucose, or improve engraftment and revascularization of transplanted islets or beta cells. Additionally, methods of using pFUS are provided for modulating paracrine secretion in the pancreas, islets, beta cells, or stem cells, or at a transplantation site to therapeutically alter levels of various factors including, without limitation, cytokines, growth factors, angiogenic factors, and cell adhesion molecules.

Disclosed is an anticoagulant manganese-containing stem cell coating, a preparation method and use thereof, which belong to the technical field of stem cell therapy. The preparation method includes the following steps: adding tannic acid, MnCl2·4H2O, and heparin sodium into a mesenchymal stem cell (MSC) suspension, mixing evenly to allow incubation to obtain an incubated stem cell solution, centrifuging the incubated stem cell solution, and collecting a resulting precipitate to obtain the anticoagulant manganese-containing stem cell coating.

The invention relates to a method for regulating osteogenic differentiation of periodontal ligament stem cells in an inflammatory microenvironment based on a stem cell-derived extracellular matrix. The method comprises the following steps: 1) separating and identifying bone marrow cells BMCs and periodontal ligament cells PDLCs; (2) preparing a bone marrow stem cell derived extracellular matrix B-ECM and a periodontal ligament stem cell derived extracellular matrix P-ECM; 3) intervening PDLSCs in an inflammation microenvironment by using the B-ECM and the P-ECM obtained in the step 2), and 4) performing animal experiment.The adverse effect of inflammation on the osteogenic differentiation capacity of periodontal ligament stem cells in the stem cell treatment process is reversed, so that a basis is provided for developing a novel periodontitis regeneration treatment strategy based on an ECM stent.

The invention discloses a bispecific antibody-UC-MSCs preparation for targeting prostate diseases as well as preparation and application of the bispecific antibody-UC-MSCs preparation. The preparation comprises a bispecific antibody BsAb-1 and human umbilical cord mesenchymal stem cells (UC-MSCs), the BsAb-1 is formed by connecting an anti-CD105 single-domain antibody, an anti-PSCA single-domain antibody and a flexible peptide linker in series, wherein the amino acid sequence of the BsAb-1 is as shown in SEQ ID NO: 4. According to the preparation, the UC-MSCs are delivered to a prostate focus through the targeting bridge effect of BsAb-1, the focus enrichment amount within 72 hours is increased by 6.3 times compared with that of pure UC-MSCs, and meanwhile retention of non-target organs such as the liver and the spleen is reduced. The preparation can effectively relieve inflammatory response and fibrosis of chronic prostatitis, and the curative effect of the preparation is remarkably superior to that of pure UC-MSCs treatment. Precise targeted treatment of prostate diseases is achieved, the curative effect is remarkably better than that of a traditional stem cell therapy method, and high clinical application value is achieved.

The invention discloses an arthritis stem cell therapeutic drug screening device and using and screening methods, and belongs to the field of medical instruments, the arthritis stem cell therapeutic drug screening device comprises a cell culture module, a drug processing module, an organ chip simulation module and a data analysis module; the cell culture module is used for amplifying and differentiating the stem cells and maintaining the physiological state of the stem cells; the medicine processing module is used for accurately adding a medicine to be screened into the stem cell culture system; the organ chip simulation module is used for simulating the pathological environment of arthritis; and the data analysis module is used for collecting and analyzing experimental data in the organ chip simulation module. According to the arthritis stem cell treatment drug screening device, stem cells are amplified and differentiated, drugs to be screened are directly added into a stem cell culture system, the pathological environment of arthritis is simulated, the influence of the drugs on cartilage cells is evaluated, and experimental data are collected and analyzed, so that the optimal drug combination is confirmed and optimized; the medicine screening efficiency is improved and the cost is reduced.

The present disclosure describes electrically stimulating biological systems using meshes, wherein the mesh comprises nanoscale wires and / or nanoelectronics. These may be embedded as a scaffold in biological structures, such as tissues, organoids, organs, organisms, and the like. These may be connectable to an external device to determine a property of the scaffold and / or to apply a stimulus to the biological structure. Certain embodiments are Al-driven systems designed for applications such as drug screening, stem cell therapy, or the like. In addition, some embodiments are directed to predictive models that can be used to predict and / or control the biological structure. For example, certain cells may be caused to mature more quickly, and / or the functionality of the biological structure may be enhanced or inhibited by using such models to apply suitable electrical stimuli to the biological structure, and / or portions of the biological structure.

The invention relates to a biological value method for evaluating the inflammation inhibition function of mesenchymal stem cells, and belongs to the technical field of stem cell treatment and biological evaluation of inflammatory diseases. The method provided by the invention has high sensitivity, high specificity and good repeatability, and is suitable for the titer evaluation of MSCs in the treatment of various inflammatory diseases. By introducing an IFNGR1 molecular index and a quantitative threshold judgment standard, a standardized and high-efficiency evaluation system from an evaluation mode depending on a'complex function experiment 'to a'molecular detection' is realized, and an innovative solution is creatively provided for standardized evaluation of the MSCs inflammation inhibition titer.

The invention discloses an in-vitro amplification method of bone marrow mesenchymal stem cells, which comprises the following steps: taking DMEM (Dulbecco Modified Eagle Medium) as a basic culture medium, and adding platelet lysate (PL), L-glutamine, epidermal growth factor (EGF), fibroblast growth factor (FGF) and endothelial growth factor (VEGF); inoculating the separated and purified bone marrow mesenchymal stem cells on a three-dimensional porous scaffold, and placing the three-dimensional porous scaffold in a dynamic culture system; periodic mechanical stimulation is applied under the low-oxygen condition; and replacing the culture medium at set intervals, and carrying out periodic culture until the cell density reaches 1 * 10 < 6 >-5 * 10 < 6 > cells / mL. The invention relates to the technical field of stem cell culture. According to the in-vitro amplification method for the bone marrow mesenchymal stem cells, a culture medium formula is optimized, a three-dimensional dynamic culture system is combined, the cell amplification efficiency and quality are improved, and powerful support is provided for stem cell treatment.

A blood product containing peripheral blood mononuclear cells (PBMCs) in an amount of at least 4 million cells per milliliter and human chorionic gonadotropin (HCG in an amount of at least 150 international units (IU) per milliliter. A method of preparing the blood product, including applying HCG to a female patient, then obtaining PBMCs from the female patient, then adding HCG to the obtained PBMCs. A method of culturing PBMCs, including applying HCG to a female patient, then culturing PBMCs obtained from the female patient at a time after the HCG was applied to the patient. A method of in vitro fertilization, including applying HCG to a female patient, culturing PBMCs obtained from the patient after the HCG was applied to the patient, introducing the cultured PBMCs into the uterus of the patient, and transferring at least one embryo into the uterus of the patient.